3-(2-chloroethoxy)benzaldehyde | 753493-35-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(2-chloroethoxy)benzaldehyde
• CAS: 753493-35-5
• 化学式: C₉H₉ClO₂
• mdl: MFCD08447746
• 分子量: 184.622
• InChiKey: JGWWHFLXOVGTRU-UHFFFAOYSA-N

物化性质

• 沸点：
  300.2±17.0 °C(Predicted)
• 密度：
  1.206±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-chloroethoxy)benzaldehyde 在 四丁基氟化铵 、 sodium hydride 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors

  摘要：

  A new class of dual-acting racemic thromboxane receptor antagonist/thromboxane synthase inhibitors is reported, based on the novel approach of linking the known thromboxane synthase inhibitors (TXSI) dazoxiben (2) or isbogrel(11) (separately) to thromboxane receptor antagonists (TXRA) from the 1,3-dioxane series, such as ICI 192605 (10). Dual activity was observed in vitro with inhibition of human microsomal thromboxane synthase in the range IC50 = 0.01-1.0 mu M and receptor antagonist activity by inhibition of U46619-induced human platelet aggregation in the range pA(2) = 5.5-7.0. The in vitro results also showed that very large groups could be tolerated at the selected substitution positions of the TXRA and TXSI components. Oral activity was observed in ex vivo tests in both rats and dogs at a dose of 10 mg/kg. Thus, (E)-7-[4-[[4-[(2SR,4SR,5RS)-5-[(Z)-5-carboxypent-2-enyl]-4-(2-hydroxyphenyl)-1,3-dioxan-2-yl]benzyl]oxy]phenyl]-7-(3-pyridyl)hept-6-enoic acid (110) was both an antagonist (pA(2) = 6.7) and a synthase inhibitor (IC50 = 0.02 mu M). On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity [concentration ratio >64 (rat, 3 h) and >59 +/- 11.3 (dog, 2 h) vs ex vivo U46619-induced platelet aggregation]. Inhibition of thromboxane synthase at the respective time points in these experiments was 81 +/- 4.4% (rat) and 69 +/- 4.8% (dog).

  DOI：

  10.1021/jm00010a005
• 作为产物：
  描述：

  2-氯乙基对甲苯磺酸酯 、 间羟基苯甲醛 在 potassium carbonate 作用下， 以 丁酮 为溶剂， 生成 3-(2-chloroethoxy)benzaldehyde
  参考文献：
  名称：

  A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors

  摘要：

  A new class of dual-acting racemic thromboxane receptor antagonist/thromboxane synthase inhibitors is reported, based on the novel approach of linking the known thromboxane synthase inhibitors (TXSI) dazoxiben (2) or isbogrel(11) (separately) to thromboxane receptor antagonists (TXRA) from the 1,3-dioxane series, such as ICI 192605 (10). Dual activity was observed in vitro with inhibition of human microsomal thromboxane synthase in the range IC50 = 0.01-1.0 mu M and receptor antagonist activity by inhibition of U46619-induced human platelet aggregation in the range pA(2) = 5.5-7.0. The in vitro results also showed that very large groups could be tolerated at the selected substitution positions of the TXRA and TXSI components. Oral activity was observed in ex vivo tests in both rats and dogs at a dose of 10 mg/kg. Thus, (E)-7-[4-[[4-[(2SR,4SR,5RS)-5-[(Z)-5-carboxypent-2-enyl]-4-(2-hydroxyphenyl)-1,3-dioxan-2-yl]benzyl]oxy]phenyl]-7-(3-pyridyl)hept-6-enoic acid (110) was both an antagonist (pA(2) = 6.7) and a synthase inhibitor (IC50 = 0.02 mu M). On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity [concentration ratio >64 (rat, 3 h) and >59 +/- 11.3 (dog, 2 h) vs ex vivo U46619-induced platelet aggregation]. Inhibition of thromboxane synthase at the respective time points in these experiments was 81 +/- 4.4% (rat) and 69 +/- 4.8% (dog).

  DOI：

  10.1021/jm00010a005

文献信息

• Palladium catalyzed chloroethoxylation of aromatic and heteroaromatic chlorides: an orthogonal functionalization of a chloroethoxy linker
  作者：Bálint Pethő、Dóra Vangel、János T. Csenki、Márton Zwillinger、Zoltán Novák

  DOI：10.1039/c8ob01146j

  日期：——

  A novel disconnection based on cross-coupling chemistry was designed to access pharmaceutically relevant aryl-aminoethyl ethers. The developed palladium-catalyzed functionalization of aryl- and heteroaryl chlorides with a sodium tetrakis-(2-chloroethoxy) borate salt is orthogonal to the simple nucleophilic replacement of the chloro function of the ethylene linker. The transformation enables efficient

  设计了一种基于交叉偶联化学的新型断开连接，以获取药学上相关的芳基-氨基乙基醚。用四（2-氯乙氧基）硼酸钠钠开发的钯催化的芳基和杂芳基氯化物的官能化与乙烯接头的氯官能团的简单亲核取代正交。该转化在不存在额外的外部碱的情况下实现了有效的2-氯乙氧基化。烷基卤的随后胺取代得到2-氨基乙氧基芳烃。通过合成各种芳基和杂芳基烷基醚，包括市售药物分子的中间体，证明了该方法的适用性。
• Synthesis and spasmolytic activities of 2-(1,2-benzisoxazol-3-yl)-3{[.omega.-(dialkylamino)alkoxy]phenyl}acrylonitriles
  作者：Shunsuke Naruto、Hiroyuki Mizuta、Tadahiro Sawayama、Toyokichi Yoshida、Hitoshi Uno、Katsuyoshi Kawashima、Yukinobu Sohji、Toshiaki Kadokawa、Haruki Nishimura

  DOI：10.1021/jm00352a029

  日期：1982.10

  Several 2-(1,2-benzisoxazol-3-yl)-3-[[omega-(dialkylamino)alkoxy]phenyl]acrylonitrile derivatives were synthesized and screened for potential spasmolytic activity. The effect of structural variation of these molecules on biological activities was systematically examined. Among these compounds, (Z)-2-(1,2-benzisoxazol-3-yl)-3-[2-(2-piperidinoethoxy)-phenyl]acrylonitrile (1d), (Z)-2-(1,2-benzisoxazo

  合成了几种2-（1,2-苯并恶唑-3-基）-3- [ω-（（二烷基氨基）烷氧基]苯基]丙烯腈衍生物，并筛选了潜在的解痉活性。这些分子的结构变化对生物活性的影响进行了系统地检查。这些化合物中，（Z）-2-（1,2-苯并恶唑-3-基）-3- [2-（2-哌啶子乙氧基）-苯基]丙烯腈（1d），（Z）-2-（1,2 -苯并恶唑-3-基）-3- [2-（2-吗啉代乙氧基）苯基]丙烯腈（1f）及其类似物（3c，d）在苯并异恶唑环的C5处具有甲氧基取代基，在苯甲异恶唑中表现出强的解痉活性体外和体内研究。
• Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives
  申请人：Bansal Ranju

  公开号：US20090137541A1

  公开（公告）日：2009-05-28

  The present invention provides a novel series of imidazolyl substituted steroidal and indan-1-one derivatives and salts thereof having the following general structural formulae (A and B)

  本发明提供了一种新的咪唑基取代类固醇和茚环-1-酮衍生物及其盐，其具有以下一般结构式（A和B）。
• Imidazolyl substituted steroidal and indan-1-one derivatives
  申请人：Bansal Ranju

  公开号：US08361996B2

  公开（公告）日：2013-01-29

  The present invention provides a novel series of imidazolyl substituted steroidal and indan-1-one derivatives and salts thereof having the following general structural formulae (A and B)

  本发明提供了一种新型的咪唑基取代的类固醇和吲哚-1-酮衍生物及其盐，其具有以下一般结构式（A和B）：
• NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES
  申请人：Council of Scientific and Industrial Research

  公开号：EP1934241B1

  公开（公告）日：2012-11-14